Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 477 | 2024 | 11345 | 25.360 |
Why?
|
Prostate-Specific Antigen | 250 | 2024 | 2529 | 24.690 |
Why?
|
Androgen Antagonists | 122 | 2024 | 1442 | 17.480 |
Why?
|
Prostatectomy | 156 | 2024 | 1956 | 12.480 |
Why?
|
Brachytherapy | 105 | 2024 | 1238 | 12.130 |
Why?
|
Antineoplastic Agents, Hormonal | 59 | 2021 | 1529 | 7.440 |
Why?
|
Prostate | 73 | 2024 | 1793 | 5.530 |
Why?
|
Salvage Therapy | 28 | 2023 | 1268 | 4.360 |
Why?
|
Adenocarcinoma | 64 | 2021 | 6315 | 3.590 |
Why?
|
Radiotherapy, Conformal | 22 | 2014 | 549 | 2.610 |
Why?
|
Male | 517 | 2024 | 359744 | 2.350 |
Why?
|
Neoplasm Recurrence, Local | 53 | 2023 | 9276 | 2.270 |
Why?
|
Neoplasm Staging | 102 | 2021 | 11152 | 2.180 |
Why?
|
Radiotherapy | 23 | 2021 | 1504 | 2.160 |
Why?
|
Gonadotropin-Releasing Hormone | 16 | 2016 | 1153 | 1.860 |
Why?
|
Radiotherapy, Adjuvant | 26 | 2022 | 1791 | 1.780 |
Why?
|
Cause of Death | 38 | 2020 | 3725 | 1.740 |
Why?
|
Aged | 258 | 2024 | 169152 | 1.720 |
Why?
|
Flutamide | 10 | 2012 | 95 | 1.690 |
Why?
|
Combined Modality Therapy | 51 | 2021 | 8552 | 1.640 |
Why?
|
Early Detection of Cancer | 16 | 2024 | 3202 | 1.530 |
Why?
|
Humans | 528 | 2024 | 760621 | 1.530 |
Why?
|
Testosterone | 9 | 2021 | 2470 | 1.510 |
Why?
|
Radiotherapy Dosage | 30 | 2024 | 2897 | 1.480 |
Why?
|
Watchful Waiting | 9 | 2020 | 510 | 1.470 |
Why?
|
Kallikreins | 7 | 2021 | 231 | 1.470 |
Why?
|
Digital Rectal Examination | 4 | 2014 | 40 | 1.390 |
Why?
|
Biopsy | 52 | 2021 | 6771 | 1.390 |
Why?
|
Follow-Up Studies | 95 | 2020 | 39261 | 1.350 |
Why?
|
Proportional Hazards Models | 51 | 2021 | 12531 | 1.280 |
Why?
|
Middle Aged | 234 | 2024 | 220352 | 1.280 |
Why?
|
Risk Assessment | 73 | 2024 | 24123 | 1.260 |
Why?
|
Risk Factors | 116 | 2024 | 74359 | 1.240 |
Why?
|
Regression Analysis | 37 | 2016 | 6360 | 1.230 |
Why?
|
Prognosis | 86 | 2024 | 29658 | 1.220 |
Why?
|
Pelvis | 8 | 2024 | 743 | 1.120 |
Why?
|
Rectum | 20 | 2014 | 895 | 1.060 |
Why?
|
Orchiectomy | 8 | 2016 | 470 | 1.060 |
Why?
|
Patient Selection | 24 | 2016 | 4283 | 1.030 |
Why?
|
Radiosurgery | 7 | 2023 | 1343 | 1.010 |
Why?
|
Aged, 80 and over | 95 | 2023 | 58995 | 1.010 |
Why?
|
Survival Analysis | 40 | 2020 | 10182 | 1.010 |
Why?
|
Radiation Injuries | 13 | 2019 | 1183 | 0.990 |
Why?
|
Seminal Vesicles | 11 | 2006 | 107 | 0.950 |
Why?
|
Time Factors | 62 | 2024 | 40165 | 0.940 |
Why?
|
Multivariate Analysis | 49 | 2015 | 12159 | 0.940 |
Why?
|
Neoplasms, Hormone-Dependent | 6 | 2009 | 412 | 0.930 |
Why?
|
Survival Rate | 39 | 2020 | 12808 | 0.920 |
Why?
|
Magnetic Resonance Imaging | 51 | 2023 | 36290 | 0.900 |
Why?
|
Urination Disorders | 5 | 2014 | 240 | 0.880 |
Why?
|
Rectal Diseases | 3 | 2012 | 144 | 0.870 |
Why?
|
Disease-Free Survival | 39 | 2018 | 6828 | 0.830 |
Why?
|
Treatment Outcome | 84 | 2021 | 65017 | 0.810 |
Why?
|
Treatment Failure | 25 | 2015 | 2648 | 0.800 |
Why?
|
Comorbidity | 23 | 2018 | 10551 | 0.800 |
Why?
|
Biopsy, Needle | 13 | 2014 | 1630 | 0.790 |
Why?
|
Prospective Studies | 47 | 2024 | 54303 | 0.760 |
Why?
|
Randomized Controlled Trials as Topic | 24 | 2024 | 10344 | 0.730 |
Why?
|
Chemotherapy, Adjuvant | 19 | 2019 | 3529 | 0.700 |
Why?
|
Predictive Value of Tests | 52 | 2023 | 15289 | 0.690 |
Why?
|
Risk | 22 | 2021 | 9631 | 0.660 |
Why?
|
Lymph Node Excision | 11 | 2023 | 1303 | 0.650 |
Why?
|
Age Factors | 26 | 2020 | 18416 | 0.650 |
Why?
|
Postoperative Care | 2 | 2024 | 1479 | 0.650 |
Why?
|
Androgens | 9 | 2024 | 1291 | 0.640 |
Why?
|
Androstenes | 2 | 2017 | 182 | 0.640 |
Why?
|
Neoplasm Metastasis | 13 | 2023 | 4902 | 0.630 |
Why?
|
Leuprolide | 9 | 2014 | 315 | 0.610 |
Why?
|
Radiotherapy, Intensity-Modulated | 6 | 2021 | 801 | 0.600 |
Why?
|
Cohort Studies | 49 | 2022 | 41335 | 0.600 |
Why?
|
Decision Support Techniques | 6 | 2015 | 2001 | 0.570 |
Why?
|
Lymphatic Metastasis | 8 | 2023 | 2943 | 0.570 |
Why?
|
Mass Screening | 10 | 2024 | 5423 | 0.560 |
Why?
|
Goserelin | 8 | 2014 | 127 | 0.560 |
Why?
|
Emotions | 4 | 2020 | 2734 | 0.550 |
Why?
|
Quality of Life | 20 | 2019 | 13308 | 0.520 |
Why?
|
Finasteride | 2 | 2007 | 90 | 0.520 |
Why?
|
Neoplasm Invasiveness | 21 | 2015 | 3618 | 0.500 |
Why?
|
Luteinizing Hormone | 2 | 2015 | 820 | 0.490 |
Why?
|
Androgen Receptor Antagonists | 2 | 2015 | 123 | 0.490 |
Why?
|
Tumor Burden | 5 | 2024 | 1895 | 0.490 |
Why?
|
Radiotherapy, High-Energy | 6 | 2014 | 228 | 0.480 |
Why?
|
Retrospective Studies | 70 | 2024 | 80372 | 0.470 |
Why?
|
Gastrointestinal Hemorrhage | 4 | 2007 | 1131 | 0.470 |
Why?
|
Cardiovascular Diseases | 14 | 2018 | 15757 | 0.470 |
Why?
|
Iodine Radioisotopes | 8 | 2013 | 1032 | 0.470 |
Why?
|
Tosyl Compounds | 2 | 2012 | 112 | 0.460 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 11712 | 0.460 |
Why?
|
Neoadjuvant Therapy | 11 | 2024 | 2821 | 0.450 |
Why?
|
Myocardial Infarction | 10 | 2016 | 11891 | 0.450 |
Why?
|
Carcinoma | 7 | 2007 | 2331 | 0.450 |
Why?
|
Germany | 3 | 2021 | 873 | 0.440 |
Why?
|
Life Expectancy | 6 | 2015 | 1248 | 0.430 |
Why?
|
Confidence Intervals | 9 | 2016 | 2932 | 0.430 |
Why?
|
Antineoplastic Agents | 14 | 2024 | 13630 | 0.410 |
Why?
|
Nitriles | 3 | 2013 | 956 | 0.410 |
Why?
|
Seminoma | 2 | 2015 | 134 | 0.400 |
Why?
|
Urinary Retention | 2 | 2005 | 106 | 0.400 |
Why?
|
SEER Program | 15 | 2019 | 1530 | 0.390 |
Why?
|
Drugs, Investigational | 1 | 2013 | 214 | 0.390 |
Why?
|
Testicular Neoplasms | 4 | 2015 | 801 | 0.390 |
Why?
|
Anilides | 2 | 2012 | 409 | 0.380 |
Why?
|
Lymph Nodes | 7 | 2024 | 3486 | 0.370 |
Why?
|
Volatile Organic Compounds | 1 | 2012 | 84 | 0.370 |
Why?
|
United States | 41 | 2024 | 72461 | 0.360 |
Why?
|
Breath Tests | 1 | 2012 | 297 | 0.360 |
Why?
|
Neoplasms, Second Primary | 3 | 2024 | 1056 | 0.360 |
Why?
|
Prostatic Hyperplasia | 6 | 2019 | 530 | 0.350 |
Why?
|
Practice Guidelines as Topic | 11 | 2019 | 7475 | 0.340 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 3334 | 0.330 |
Why?
|
Health Status | 4 | 2014 | 4081 | 0.330 |
Why?
|
Coronary Artery Disease | 4 | 2013 | 6659 | 0.330 |
Why?
|
Acetanilides | 1 | 2010 | 169 | 0.320 |
Why?
|
Clindamycin | 1 | 2009 | 140 | 0.320 |
Why?
|
Hypercholesterolemia | 3 | 2013 | 1155 | 0.310 |
Why?
|
Radium | 3 | 2020 | 72 | 0.310 |
Why?
|
Chromatography, Gas | 1 | 2008 | 151 | 0.310 |
Why?
|
Radiation Dosage | 6 | 2021 | 1958 | 0.300 |
Why?
|
Algorithms | 8 | 2021 | 13981 | 0.300 |
Why?
|
Estrogens | 1 | 2014 | 1520 | 0.300 |
Why?
|
Defecation | 2 | 2006 | 190 | 0.290 |
Why?
|
Urethra | 4 | 2021 | 406 | 0.290 |
Why?
|
Myocardial Revascularization | 1 | 2011 | 841 | 0.280 |
Why?
|
Drug Approval | 2 | 2013 | 816 | 0.280 |
Why?
|
Transducers | 1 | 2008 | 240 | 0.280 |
Why?
|
Kaplan-Meier Estimate | 8 | 2018 | 6544 | 0.280 |
Why?
|
Databases, Factual | 10 | 2021 | 8035 | 0.270 |
Why?
|
Enzyme Inhibitors | 3 | 2007 | 3726 | 0.270 |
Why?
|
Angina Pectoris | 1 | 2010 | 969 | 0.270 |
Why?
|
Guideline Adherence | 3 | 2013 | 2283 | 0.260 |
Why?
|
Skin Tests | 1 | 2008 | 637 | 0.260 |
Why?
|
Antibiotic Prophylaxis | 2 | 2009 | 643 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3085 | 0.260 |
Why?
|
Hemorrhoids | 1 | 2005 | 19 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3205 | 0.260 |
Why?
|
Erectile Dysfunction | 6 | 2010 | 452 | 0.250 |
Why?
|
Age of Onset | 5 | 2015 | 3301 | 0.250 |
Why?
|
Radiodermatitis | 1 | 2005 | 58 | 0.250 |
Why?
|
Preoperative Care | 8 | 2009 | 2256 | 0.250 |
Why?
|
Probiotics | 1 | 2009 | 377 | 0.250 |
Why?
|
Logistic Models | 15 | 2019 | 13314 | 0.250 |
Why?
|
Actuarial Analysis | 7 | 2001 | 374 | 0.240 |
Why?
|
Markov Chains | 3 | 2020 | 968 | 0.240 |
Why?
|
Clinical Trials as Topic | 13 | 2021 | 8056 | 0.240 |
Why?
|
Computer Systems | 3 | 2003 | 470 | 0.240 |
Why?
|
Adult | 58 | 2023 | 219994 | 0.240 |
Why?
|
Diabetes Complications | 1 | 2011 | 1341 | 0.240 |
Why?
|
Muscular Dystrophy, Duchenne | 3 | 2013 | 268 | 0.230 |
Why?
|
Radiometry | 5 | 2016 | 813 | 0.230 |
Why?
|
Disease Progression | 12 | 2021 | 13502 | 0.230 |
Why?
|
Lymphatic Irradiation | 1 | 2024 | 115 | 0.230 |
Why?
|
Propensity Score | 5 | 2021 | 1928 | 0.220 |
Why?
|
Cardiovascular Agents | 1 | 2010 | 867 | 0.220 |
Why?
|
Radiation Oncology | 3 | 2019 | 563 | 0.220 |
Why?
|
Heart Diseases | 4 | 2019 | 2809 | 0.220 |
Why?
|
Recurrence | 9 | 2013 | 8482 | 0.220 |
Why?
|
Australia | 2 | 2021 | 1289 | 0.220 |
Why?
|
Urinary Bladder | 5 | 2003 | 1166 | 0.220 |
Why?
|
Drug Therapy, Combination | 5 | 2020 | 6498 | 0.220 |
Why?
|
5-alpha Reductase Inhibitors | 2 | 2019 | 117 | 0.210 |
Why?
|
BRCA2 Protein | 2 | 2019 | 798 | 0.210 |
Why?
|
Sensitivity and Specificity | 15 | 2014 | 14660 | 0.210 |
Why?
|
Epidemiologic Methods | 4 | 2010 | 1343 | 0.200 |
Why?
|
Radioisotopes | 3 | 2013 | 495 | 0.200 |
Why?
|
Alopecia | 1 | 2007 | 414 | 0.200 |
Why?
|
Odds Ratio | 11 | 2019 | 9716 | 0.200 |
Why?
|
Self Medication | 1 | 2002 | 117 | 0.200 |
Why?
|
Niacin | 1 | 2002 | 119 | 0.200 |
Why?
|
Multiple Myeloma | 1 | 2019 | 5130 | 0.190 |
Why?
|
Belgium | 1 | 2021 | 118 | 0.190 |
Why?
|
Advisory Committees | 2 | 2019 | 788 | 0.190 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 6 | 2023 | 1660 | 0.190 |
Why?
|
Reproducibility of Results | 23 | 2014 | 20080 | 0.190 |
Why?
|
Coronary Artery Bypass | 1 | 2010 | 2272 | 0.180 |
Why?
|
Heart Failure | 5 | 2013 | 11847 | 0.180 |
Why?
|
New Zealand | 1 | 2021 | 355 | 0.180 |
Why?
|
Flank Pain | 1 | 2000 | 43 | 0.180 |
Why?
|
Peripheral Nervous System Neoplasms | 1 | 2001 | 133 | 0.180 |
Why?
|
Career Choice | 1 | 2007 | 754 | 0.180 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2282 | 0.180 |
Why?
|
Chi-Square Distribution | 5 | 2018 | 3465 | 0.170 |
Why?
|
Stroke | 2 | 2014 | 9962 | 0.170 |
Why?
|
Prostatic Diseases | 1 | 2000 | 57 | 0.170 |
Why?
|
Urethritis | 1 | 1999 | 24 | 0.170 |
Why?
|
Adrenergic alpha-1 Receptor Antagonists | 1 | 1999 | 24 | 0.170 |
Why?
|
Forecasting | 8 | 2005 | 2932 | 0.170 |
Why?
|
Aspirin | 2 | 2012 | 3364 | 0.170 |
Why?
|
Hemibody Irradiation | 1 | 2019 | 4 | 0.170 |
Why?
|
Piperazines | 1 | 2010 | 2525 | 0.170 |
Why?
|
Pathology, Clinical | 1 | 2003 | 375 | 0.170 |
Why?
|
Kidney Pelvis | 1 | 2000 | 188 | 0.170 |
Why?
|
Hemoglobins | 2 | 2002 | 1521 | 0.170 |
Why?
|
Incidence | 13 | 2023 | 21392 | 0.170 |
Why?
|
Postoperative Complications | 9 | 2014 | 15697 | 0.170 |
Why?
|
Healthcare Disparities | 5 | 2014 | 3388 | 0.170 |
Why?
|
Renal Artery Obstruction | 1 | 2000 | 224 | 0.160 |
Why?
|
Hematuria | 1 | 2000 | 233 | 0.160 |
Why?
|
Teaching | 1 | 2007 | 1169 | 0.160 |
Why?
|
Gastrointestinal Diseases | 3 | 2024 | 1190 | 0.160 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2012 | 4024 | 0.160 |
Why?
|
Illinois | 1 | 2019 | 118 | 0.160 |
Why?
|
Spinal Muscular Atrophies of Childhood | 2 | 2013 | 114 | 0.160 |
Why?
|
Faculty, Medical | 1 | 2007 | 1192 | 0.150 |
Why?
|
Taxoids | 3 | 2024 | 669 | 0.150 |
Why?
|
Analysis of Variance | 8 | 2013 | 6238 | 0.150 |
Why?
|
Drug Interactions | 1 | 2002 | 1428 | 0.150 |
Why?
|
Genomics | 3 | 2019 | 5794 | 0.150 |
Why?
|
Toxoplasmosis, Cerebral | 1 | 1997 | 19 | 0.150 |
Why?
|
Quality-Adjusted Life Years | 4 | 2016 | 1724 | 0.150 |
Why?
|
Patient Satisfaction | 4 | 2013 | 3448 | 0.150 |
Why?
|
Thallium Radioisotopes | 1 | 1997 | 138 | 0.150 |
Why?
|
ROC Curve | 5 | 2014 | 3568 | 0.140 |
Why?
|
Diabetes Mellitus | 3 | 2013 | 5889 | 0.140 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2008 | 2919 | 0.140 |
Why?
|
Endpoint Determination | 1 | 2020 | 597 | 0.140 |
Why?
|
Unnecessary Procedures | 2 | 2011 | 413 | 0.140 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2021 | 547 | 0.140 |
Why?
|
Lymphoma, AIDS-Related | 1 | 1997 | 79 | 0.140 |
Why?
|
Patient Participation | 2 | 2023 | 1439 | 0.140 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2011 | 3455 | 0.140 |
Why?
|
Tissue Extracts | 2 | 2013 | 140 | 0.140 |
Why?
|
Lip Neoplasms | 1 | 1996 | 36 | 0.130 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 1996 | 42 | 0.130 |
Why?
|
Gastrointestinal Tract | 3 | 2024 | 830 | 0.130 |
Why?
|
Cardiac Myosins | 1 | 2016 | 127 | 0.130 |
Why?
|
Urinary Incontinence | 4 | 2009 | 495 | 0.130 |
Why?
|
Genital Neoplasms, Male | 3 | 2006 | 68 | 0.130 |
Why?
|
Neuroleptic Malignant Syndrome | 1 | 2016 | 74 | 0.130 |
Why?
|
Societies, Medical | 4 | 2019 | 3905 | 0.130 |
Why?
|
Immobilization | 3 | 2012 | 230 | 0.130 |
Why?
|
Carcinoma, Embryonal | 1 | 2015 | 37 | 0.130 |
Why?
|
Pilot Projects | 4 | 2023 | 8555 | 0.130 |
Why?
|
Socioeconomic Factors | 5 | 2015 | 7806 | 0.120 |
Why?
|
Patient Care | 1 | 2021 | 624 | 0.120 |
Why?
|
Patient Care Planning | 3 | 2004 | 908 | 0.120 |
Why?
|
Catheterization | 3 | 2012 | 1432 | 0.120 |
Why?
|
Preventive Health Services | 1 | 2019 | 570 | 0.120 |
Why?
|
Body Mass Index | 2 | 2010 | 12914 | 0.120 |
Why?
|
Chicago | 1 | 2015 | 244 | 0.120 |
Why?
|
Myosin Heavy Chains | 1 | 2016 | 402 | 0.120 |
Why?
|
Liver | 2 | 2024 | 7509 | 0.120 |
Why?
|
Lung Neoplasms | 4 | 2019 | 13262 | 0.120 |
Why?
|
Urogenital System | 2 | 2023 | 88 | 0.120 |
Why?
|
Contrast Media | 2 | 2005 | 5305 | 0.120 |
Why?
|
Postoperative Period | 4 | 2010 | 1818 | 0.120 |
Why?
|
Kinetics | 4 | 2019 | 6377 | 0.120 |
Why?
|
Disability Evaluation | 2 | 2014 | 1826 | 0.120 |
Why?
|
Penis | 3 | 2013 | 212 | 0.120 |
Why?
|
Androstenols | 1 | 2013 | 25 | 0.120 |
Why?
|
Evidence-Based Medicine | 5 | 2014 | 3696 | 0.120 |
Why?
|
Estramustine | 1 | 2013 | 36 | 0.120 |
Why?
|
Diagnosis, Computer-Assisted | 2 | 2010 | 707 | 0.110 |
Why?
|
Fecal Incontinence | 2 | 2009 | 241 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2019 | 995 | 0.110 |
Why?
|
Mitoxantrone | 1 | 2013 | 149 | 0.110 |
Why?
|
Life Tables | 2 | 2004 | 365 | 0.110 |
Why?
|
Carcinoma, Renal Cell | 5 | 2006 | 3218 | 0.110 |
Why?
|
Colorectal Neoplasms | 1 | 2013 | 6853 | 0.110 |
Why?
|
Lewy Body Disease | 1 | 2016 | 252 | 0.110 |
Why?
|
Prostheses and Implants | 2 | 2011 | 1273 | 0.110 |
Why?
|
Drug Administration Schedule | 4 | 2010 | 4899 | 0.110 |
Why?
|
User-Computer Interface | 1 | 2000 | 1403 | 0.110 |
Why?
|
Probability | 4 | 2022 | 2475 | 0.110 |
Why?
|
BRCA1 Protein | 1 | 2019 | 1147 | 0.110 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2557 | 0.110 |
Why?
|
Kidney Neoplasms | 6 | 2006 | 4312 | 0.110 |
Why?
|
Insurance Coverage | 2 | 2014 | 1939 | 0.100 |
Why?
|
Urinary Bladder Neoplasms | 4 | 2020 | 2276 | 0.100 |
Why?
|
Dystroglycans | 1 | 2012 | 62 | 0.100 |
Why?
|
Metabolome | 1 | 2019 | 982 | 0.100 |
Why?
|
Anuria | 1 | 1992 | 15 | 0.100 |
Why?
|
Amyloidosis | 1 | 2019 | 817 | 0.100 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1997 | 1067 | 0.100 |
Why?
|
Health Status Disparities | 2 | 2014 | 1830 | 0.100 |
Why?
|
Pandemics | 3 | 2021 | 8624 | 0.100 |
Why?
|
Pathology, Molecular | 1 | 2015 | 329 | 0.100 |
Why?
|
Phenylthiohydantoin | 1 | 2013 | 204 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2021 | 1152 | 0.100 |
Why?
|
Metformin | 1 | 2020 | 912 | 0.100 |
Why?
|
Spermatic Cord Torsion | 1 | 1992 | 73 | 0.100 |
Why?
|
Organs at Risk | 1 | 2014 | 358 | 0.100 |
Why?
|
Organ Size | 3 | 2013 | 2254 | 0.100 |
Why?
|
Muscular Diseases | 1 | 2016 | 551 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2326 | 0.100 |
Why?
|
Observer Variation | 4 | 2009 | 2601 | 0.100 |
Why?
|
Medical Oncology | 3 | 2014 | 2313 | 0.100 |
Why?
|
Neoplasm Proteins | 1 | 2004 | 3610 | 0.100 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3844 | 0.090 |
Why?
|
Cyproterone Acetate | 1 | 2010 | 5 | 0.090 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2012 | 352 | 0.090 |
Why?
|
Exhalation | 1 | 2012 | 181 | 0.090 |
Why?
|
Decision Making | 2 | 2023 | 3925 | 0.090 |
Why?
|
Reference Values | 4 | 2010 | 4925 | 0.090 |
Why?
|
Quality Assurance, Health Care | 2 | 2007 | 2176 | 0.090 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7408 | 0.090 |
Why?
|
Muscular Atrophy, Spinal | 1 | 2014 | 258 | 0.090 |
Why?
|
Population Surveillance | 3 | 2015 | 2608 | 0.090 |
Why?
|
Referral and Consultation | 3 | 2019 | 3598 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2024 | 3959 | 0.090 |
Why?
|
Neoplasms | 6 | 2020 | 22072 | 0.090 |
Why?
|
False Negative Reactions | 1 | 2011 | 573 | 0.090 |
Why?
|
Chemoprevention | 1 | 2012 | 326 | 0.090 |
Why?
|
Attitude to Health | 1 | 2019 | 2029 | 0.090 |
Why?
|
Mucus | 1 | 2012 | 342 | 0.090 |
Why?
|
Boston | 2 | 2021 | 9280 | 0.090 |
Why?
|
Evaluation Studies as Topic | 2 | 2005 | 1628 | 0.090 |
Why?
|
Cesium Radioisotopes | 1 | 2009 | 38 | 0.090 |
Why?
|
Muscular Dystrophies | 1 | 2012 | 389 | 0.090 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2015 | 494 | 0.090 |
Why?
|
Sulfonamides | 1 | 1999 | 1977 | 0.080 |
Why?
|
Health Literacy | 1 | 2015 | 440 | 0.080 |
Why?
|
Massachusetts | 3 | 2009 | 8803 | 0.080 |
Why?
|
Melanoma | 1 | 2008 | 5697 | 0.080 |
Why?
|
Palladium | 1 | 2009 | 68 | 0.080 |
Why?
|
Penile Neoplasms | 3 | 2000 | 162 | 0.080 |
Why?
|
Case-Control Studies | 5 | 2020 | 22053 | 0.080 |
Why?
|
Edema | 1 | 2013 | 769 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2014 | 968 | 0.080 |
Why?
|
Walking | 3 | 2013 | 1189 | 0.080 |
Why?
|
Drug Design | 2 | 2004 | 1061 | 0.080 |
Why?
|
Interleukins | 1 | 2013 | 785 | 0.080 |
Why?
|
Urinary Incontinence, Stress | 2 | 2010 | 181 | 0.080 |
Why?
|
Diphosphonates | 1 | 2013 | 638 | 0.080 |
Why?
|
Respiratory System | 1 | 2012 | 557 | 0.080 |
Why?
|
Exercise Therapy | 2 | 2013 | 919 | 0.080 |
Why?
|
False Positive Reactions | 1 | 2011 | 956 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1997 | 2197 | 0.080 |
Why?
|
Skin Neoplasms | 1 | 2008 | 5799 | 0.080 |
Why?
|
Alzheimer Disease | 1 | 2010 | 8547 | 0.080 |
Why?
|
Oligopeptides | 1 | 2013 | 1187 | 0.080 |
Why?
|
Benzamides | 1 | 2013 | 1369 | 0.070 |
Why?
|
Cancer Care Facilities | 1 | 2011 | 424 | 0.070 |
Why?
|
Arachidonic Acids | 1 | 2008 | 294 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2024 | 8515 | 0.070 |
Why?
|
Angioplasty | 1 | 2010 | 361 | 0.070 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2009 | 345 | 0.070 |
Why?
|
Fertility | 1 | 1992 | 773 | 0.070 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2012 | 471 | 0.070 |
Why?
|
Imidazoles | 1 | 2013 | 1180 | 0.070 |
Why?
|
Gases | 1 | 2008 | 203 | 0.070 |
Why?
|
Diarrhea | 2 | 2012 | 1319 | 0.070 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2009 | 187 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2011 | 12293 | 0.070 |
Why?
|
Self Report | 2 | 2020 | 3711 | 0.070 |
Why?
|
Alcohol Drinking | 1 | 2020 | 4013 | 0.070 |
Why?
|
Meta-Analysis as Topic | 1 | 2011 | 1376 | 0.070 |
Why?
|
Penile Erection | 1 | 2006 | 100 | 0.070 |
Why?
|
Bone Marrow | 1 | 1997 | 2912 | 0.070 |
Why?
|
Otitis Media | 1 | 1989 | 285 | 0.070 |
Why?
|
Internship and Residency | 1 | 2007 | 5870 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 934 | 0.070 |
Why?
|
Geriatric Assessment | 1 | 2014 | 1405 | 0.070 |
Why?
|
Homeodomain Proteins | 1 | 2016 | 2414 | 0.070 |
Why?
|
Liver Function Tests | 1 | 2007 | 524 | 0.070 |
Why?
|
Adolescent | 14 | 2020 | 87810 | 0.070 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2023 | 3765 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 17790 | 0.070 |
Why?
|
Granuloma | 1 | 2008 | 327 | 0.070 |
Why?
|
Nomograms | 2 | 2023 | 238 | 0.070 |
Why?
|
Patient Care Team | 2 | 2019 | 2511 | 0.070 |
Why?
|
Electromagnetic Phenomena | 1 | 2007 | 161 | 0.070 |
Why?
|
Heptanoic Acids | 1 | 2007 | 347 | 0.060 |
Why?
|
Income | 1 | 2014 | 1875 | 0.060 |
Why?
|
Software | 1 | 2000 | 4419 | 0.060 |
Why?
|
Diagnosis, Differential | 3 | 2012 | 12965 | 0.060 |
Why?
|
Female | 27 | 2021 | 391270 | 0.060 |
Why?
|
Registries | 3 | 2011 | 8469 | 0.060 |
Why?
|
Equipment Failure Analysis | 1 | 2008 | 848 | 0.060 |
Why?
|
Abdominal Pain | 1 | 2012 | 1063 | 0.060 |
Why?
|
Exercise Test | 1 | 2013 | 2128 | 0.060 |
Why?
|
Urination | 1 | 2006 | 202 | 0.060 |
Why?
|
Multicenter Studies as Topic | 2 | 2009 | 1722 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 1999 | 3527 | 0.060 |
Why?
|
Mobility Limitation | 1 | 2009 | 402 | 0.060 |
Why?
|
Thrombin | 1 | 1988 | 593 | 0.060 |
Why?
|
Feasibility Studies | 5 | 2023 | 5201 | 0.060 |
Why?
|
United States Food and Drug Administration | 1 | 2013 | 1677 | 0.060 |
Why?
|
Heart | 3 | 2019 | 4393 | 0.060 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1881 | 0.060 |
Why?
|
Urogenital Neoplasms | 1 | 2006 | 135 | 0.060 |
Why?
|
Tourette Syndrome | 1 | 2008 | 394 | 0.060 |
Why?
|
Career Mobility | 1 | 2007 | 258 | 0.060 |
Why?
|
Models, Biological | 2 | 2005 | 9467 | 0.060 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 1824 | 0.060 |
Why?
|
Patient-Centered Care | 1 | 2014 | 1416 | 0.060 |
Why?
|
Receptors, Cell Surface | 1 | 2013 | 2825 | 0.060 |
Why?
|
Hypertension | 3 | 2013 | 8594 | 0.060 |
Why?
|
Palpation | 2 | 2001 | 166 | 0.060 |
Why?
|
Prevalence | 4 | 2020 | 15687 | 0.060 |
Why?
|
Motor Activity | 1 | 2014 | 2687 | 0.060 |
Why?
|
Anxiety Disorders | 1 | 2015 | 2714 | 0.060 |
Why?
|
Urethral Obstruction | 1 | 2003 | 56 | 0.060 |
Why?
|
Italy | 3 | 2013 | 841 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2016 | 14495 | 0.050 |
Why?
|
Receptors, LHRH | 1 | 2003 | 158 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2006 | 629 | 0.050 |
Why?
|
Middle East | 1 | 2023 | 230 | 0.050 |
Why?
|
Linear Models | 3 | 2007 | 5877 | 0.050 |
Why?
|
Heart-Assist Devices | 1 | 2013 | 1291 | 0.050 |
Why?
|
Precipitating Factors | 1 | 2002 | 51 | 0.050 |
Why?
|
Guidelines as Topic | 2 | 2019 | 1392 | 0.050 |
Why?
|
Intraoperative Care | 2 | 2003 | 768 | 0.050 |
Why?
|
Ejaculation | 1 | 2002 | 59 | 0.050 |
Why?
|
Proctitis | 1 | 2002 | 41 | 0.050 |
Why?
|
Robotics | 1 | 2010 | 874 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 5 | 2012 | 8950 | 0.050 |
Why?
|
Prothrombin Time | 1 | 2002 | 116 | 0.050 |
Why?
|
Europe | 2 | 2023 | 3441 | 0.050 |
Why?
|
Antipsychotic Agents | 1 | 2016 | 3061 | 0.050 |
Why?
|
Hearing Loss, Sensorineural | 1 | 1989 | 781 | 0.050 |
Why?
|
Models, Theoretical | 2 | 2009 | 3562 | 0.050 |
Why?
|
Neoplasms, Experimental | 1 | 1988 | 1229 | 0.050 |
Why?
|
Anal Canal | 1 | 2005 | 372 | 0.050 |
Why?
|
Arthroscopy | 1 | 2009 | 960 | 0.050 |
Why?
|
Quality Improvement | 2 | 2014 | 3836 | 0.050 |
Why?
|
Marital Status | 2 | 2015 | 433 | 0.050 |
Why?
|
Models, Statistical | 1 | 2016 | 5075 | 0.050 |
Why?
|
Acetylglucosaminidase | 1 | 2001 | 67 | 0.050 |
Why?
|
Equipment Design | 2 | 2008 | 3520 | 0.050 |
Why?
|
Radiography | 3 | 2006 | 6965 | 0.050 |
Why?
|
Health Services Research | 1 | 2009 | 1810 | 0.050 |
Why?
|
Insurance, Health | 1 | 2014 | 2501 | 0.050 |
Why?
|
Vascular Surgical Procedures | 2 | 2001 | 1475 | 0.050 |
Why?
|
Biosensing Techniques | 1 | 2008 | 677 | 0.050 |
Why?
|
Selection Bias | 1 | 2003 | 358 | 0.050 |
Why?
|
Software Validation | 1 | 2001 | 59 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 5251 | 0.050 |
Why?
|
Mentors | 1 | 2007 | 661 | 0.050 |
Why?
|
Pyrroles | 1 | 2007 | 1137 | 0.050 |
Why?
|
Laparoscopy | 2 | 2010 | 2147 | 0.050 |
Why?
|
Radiation Protection | 1 | 2005 | 425 | 0.050 |
Why?
|
Radionuclide Imaging | 1 | 2005 | 1975 | 0.050 |
Why?
|
Young Adult | 9 | 2020 | 58741 | 0.050 |
Why?
|
Germinoma | 1 | 2001 | 132 | 0.050 |
Why?
|
Child, Preschool | 9 | 2016 | 42063 | 0.050 |
Why?
|
Electric Stimulation Therapy | 1 | 2007 | 613 | 0.050 |
Why?
|
Delphi Technique | 2 | 2014 | 829 | 0.050 |
Why?
|
Renal Veins | 1 | 2001 | 102 | 0.050 |
Why?
|
Body Composition | 2 | 2024 | 2419 | 0.050 |
Why?
|
Motor Neurons | 1 | 2006 | 865 | 0.050 |
Why?
|
Calibration | 2 | 2000 | 816 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2002 | 881 | 0.040 |
Why?
|
Cross-Sectional Studies | 5 | 2019 | 25942 | 0.040 |
Why?
|
Morbidity | 2 | 2019 | 1765 | 0.040 |
Why?
|
Indoles | 1 | 2008 | 1829 | 0.040 |
Why?
|
North America | 1 | 2023 | 1284 | 0.040 |
Why?
|
Coronary Disease | 1 | 2014 | 5990 | 0.040 |
Why?
|
Urology | 2 | 2019 | 423 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2002 | 998 | 0.040 |
Why?
|
Hormones | 1 | 2023 | 867 | 0.040 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2000 | 90 | 0.040 |
Why?
|
Depression | 2 | 2018 | 8044 | 0.040 |
Why?
|
Mutation | 3 | 2019 | 29932 | 0.040 |
Why?
|
Peritoneum | 1 | 2000 | 224 | 0.040 |
Why?
|
Vascular Neoplasms | 1 | 2001 | 167 | 0.040 |
Why?
|
Stromal Cells | 1 | 2024 | 1326 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7343 | 0.040 |
Why?
|
Antigens, Surface | 1 | 2023 | 1608 | 0.040 |
Why?
|
Muscle, Skeletal | 3 | 2024 | 4925 | 0.040 |
Why?
|
Prodrugs | 1 | 2000 | 259 | 0.040 |
Why?
|
Perineum | 1 | 2000 | 208 | 0.040 |
Why?
|
Apoptosis | 1 | 1994 | 9501 | 0.040 |
Why?
|
Fractures, Bone | 1 | 2010 | 2041 | 0.040 |
Why?
|
Benchmarking | 2 | 2018 | 1044 | 0.040 |
Why?
|
Stents | 1 | 2010 | 3314 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2020 | 384 | 0.040 |
Why?
|
Neovascularization, Pathologic | 1 | 2008 | 2640 | 0.040 |
Why?
|
Tomography | 1 | 2000 | 411 | 0.040 |
Why?
|
Vena Cava, Inferior | 1 | 2001 | 458 | 0.040 |
Why?
|
Psychomotor Performance | 1 | 2006 | 1878 | 0.040 |
Why?
|
Epilepsy | 1 | 2013 | 3267 | 0.040 |
Why?
|
Genes, p16 | 1 | 1997 | 159 | 0.040 |
Why?
|
Nephrectomy | 2 | 2001 | 1016 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2006 | 5253 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9411 | 0.040 |
Why?
|
Phenylurea Compounds | 1 | 2020 | 529 | 0.040 |
Why?
|
California | 1 | 2021 | 1416 | 0.040 |
Why?
|
Standard of Care | 1 | 2021 | 552 | 0.040 |
Why?
|
Anticoagulants | 1 | 2012 | 4897 | 0.030 |
Why?
|
Ventricular Fibrillation | 1 | 1999 | 539 | 0.030 |
Why?
|
Cell Division | 2 | 1994 | 4463 | 0.030 |
Why?
|
Bone Marrow Neoplasms | 1 | 1997 | 101 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 1997 | 8986 | 0.030 |
Why?
|
Urologic Neoplasms | 1 | 2000 | 320 | 0.030 |
Why?
|
Child | 9 | 2016 | 79806 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1999 | 640 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2021 | 718 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2013 | 5325 | 0.030 |
Why?
|
Mortality | 2 | 2019 | 2916 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2010 | 3986 | 0.030 |
Why?
|
Hormone Replacement Therapy | 2 | 2002 | 755 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2138 | 0.030 |
Why?
|
HLA-DR Antigens | 1 | 1997 | 630 | 0.030 |
Why?
|
Deoxycytidine | 1 | 1999 | 873 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 1999 | 1007 | 0.030 |
Why?
|
Lung | 2 | 2012 | 9994 | 0.030 |
Why?
|
Consensus | 2 | 2014 | 3113 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1997 | 698 | 0.030 |
Why?
|
Acute Disease | 1 | 2005 | 7269 | 0.030 |
Why?
|
Patient Protection and Affordable Care Act | 2 | 2014 | 1200 | 0.030 |
Why?
|
Radiology | 2 | 2021 | 2102 | 0.030 |
Why?
|
Syndrome | 1 | 2000 | 3280 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2010 | 357 | 0.030 |
Why?
|
Gynecomastia | 1 | 2014 | 87 | 0.030 |
Why?
|
Spinal Cord Injuries | 1 | 2001 | 924 | 0.030 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1997 | 662 | 0.030 |
Why?
|
Infection Control | 1 | 2021 | 983 | 0.030 |
Why?
|
Minority Health | 1 | 2014 | 81 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2021 | 21025 | 0.030 |
Why?
|
Survival | 1 | 2013 | 161 | 0.030 |
Why?
|
Urinary Catheterization | 1 | 2014 | 198 | 0.030 |
Why?
|
United States Department of Veterans Affairs | 1 | 2018 | 919 | 0.030 |
Why?
|
Epilepsy, Tonic-Clonic | 1 | 2013 | 53 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 2015 | 631 | 0.030 |
Why?
|
Philadelphia | 1 | 1993 | 265 | 0.030 |
Why?
|
Epilepsy, Absence | 1 | 2013 | 49 | 0.030 |
Why?
|
History, 21st Century | 1 | 2019 | 1575 | 0.030 |
Why?
|
Neurologic Examination | 1 | 2016 | 916 | 0.030 |
Why?
|
Heterozygote | 1 | 2019 | 2798 | 0.030 |
Why?
|
Brain | 2 | 2012 | 26951 | 0.030 |
Why?
|
Mannosyltransferases | 1 | 2012 | 23 | 0.030 |
Why?
|
Pentosyltransferases | 1 | 2012 | 62 | 0.030 |
Why?
|
Urine | 1 | 2014 | 363 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2007 | 12427 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2004 | 20509 | 0.030 |
Why?
|
Biology | 1 | 1994 | 290 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1791 | 0.030 |
Why?
|
Research Design | 2 | 2007 | 6180 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 1996 | 861 | 0.020 |
Why?
|
Catheters, Indwelling | 1 | 2014 | 428 | 0.020 |
Why?
|
Pregnenediones | 1 | 2011 | 29 | 0.020 |
Why?
|
Hospitals, University | 1 | 1993 | 568 | 0.020 |
Why?
|
Data Interpretation, Statistical | 3 | 2009 | 2696 | 0.020 |
Why?
|
Hot Flashes | 1 | 2014 | 328 | 0.020 |
Why?
|
Air | 1 | 2012 | 186 | 0.020 |
Why?
|
Cisplatin | 1 | 1997 | 1644 | 0.020 |
Why?
|
Genotype | 2 | 2016 | 12960 | 0.020 |
Why?
|
Androstadienes | 1 | 2012 | 348 | 0.020 |
Why?
|
Computer Simulation | 2 | 2005 | 6218 | 0.020 |
Why?
|
Bone Diseases, Metabolic | 1 | 2014 | 409 | 0.020 |
Why?
|
Occupational Exposure | 1 | 2001 | 1809 | 0.020 |
Why?
|
RNA-Induced Silencing Complex | 1 | 2010 | 56 | 0.020 |
Why?
|
Epitopes | 1 | 1997 | 2503 | 0.020 |
Why?
|
Prednisolone | 1 | 2011 | 327 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2019 | 2717 | 0.020 |
Why?
|
American Cancer Society | 1 | 2010 | 66 | 0.020 |
Why?
|
Paclitaxel | 1 | 1997 | 1736 | 0.020 |
Why?
|
Adenoma | 1 | 2001 | 2148 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 2 | 2002 | 4048 | 0.020 |
Why?
|
Ventilators, Mechanical | 1 | 2012 | 287 | 0.020 |
Why?
|
Enoxaparin | 1 | 2012 | 397 | 0.020 |
Why?
|
Transfection | 1 | 1997 | 5781 | 0.020 |
Why?
|
Reoperation | 1 | 2000 | 4291 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2015 | 1115 | 0.020 |
Why?
|
Cell Cycle | 1 | 1997 | 2934 | 0.020 |
Why?
|
Bone Marrow Cells | 1 | 1997 | 2414 | 0.020 |
Why?
|
Phlebotomy | 1 | 2010 | 137 | 0.020 |
Why?
|
Epilepsies, Partial | 1 | 2013 | 430 | 0.020 |
Why?
|
Image Enhancement | 1 | 2000 | 2881 | 0.020 |
Why?
|
Testis | 1 | 1992 | 794 | 0.020 |
Why?
|
Surface Properties | 1 | 2012 | 1161 | 0.020 |
Why?
|
Phantoms, Imaging | 2 | 2012 | 2512 | 0.020 |
Why?
|
Muscle Proteins | 1 | 2014 | 1152 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2000 | 2628 | 0.020 |
Why?
|
Transurethral Resection of Prostate | 1 | 2009 | 85 | 0.020 |
Why?
|
Infant | 3 | 2016 | 36060 | 0.020 |
Why?
|
Oncogenes | 1 | 1994 | 1220 | 0.020 |
Why?
|
Chymases | 1 | 2008 | 73 | 0.020 |
Why?
|
Carrageenan | 1 | 2008 | 71 | 0.020 |
Why?
|
Pedigree | 1 | 2016 | 4578 | 0.020 |
Why?
|
Urologic Surgical Procedures, Male | 1 | 2008 | 80 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2016 | 1502 | 0.020 |
Why?
|
Receptor, Cannabinoid, CB2 | 1 | 2008 | 48 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2514 | 0.020 |
Why?
|
Lower Extremity | 1 | 2016 | 1194 | 0.020 |
Why?
|
Spermatozoa | 1 | 1992 | 631 | 0.020 |
Why?
|
Atrophy | 1 | 2013 | 1627 | 0.020 |
Why?
|
Radioisotope Teletherapy | 1 | 2007 | 15 | 0.020 |
Why?
|
Urinary Fistula | 1 | 2007 | 43 | 0.020 |
Why?
|
Metabolic Diseases | 1 | 2014 | 686 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2016 | 1841 | 0.020 |
Why?
|
Male Urogenital Diseases | 1 | 2007 | 48 | 0.020 |
Why?
|
Receptor, Cannabinoid, CB1 | 1 | 2008 | 138 | 0.020 |
Why?
|
Lumbosacral Plexus | 1 | 2007 | 51 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 3150 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2019 | 9530 | 0.020 |
Why?
|
Ticlopidine | 1 | 2012 | 895 | 0.020 |
Why?
|
Cryotherapy | 1 | 2007 | 161 | 0.020 |
Why?
|
International Cooperation | 1 | 2013 | 1433 | 0.020 |
Why?
|
Spinal Nerve Roots | 1 | 2007 | 121 | 0.020 |
Why?
|
Rats, Inbred Strains | 1 | 1988 | 2094 | 0.020 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2012 | 819 | 0.020 |
Why?
|
Perception | 1 | 2013 | 1195 | 0.020 |
Why?
|
Length of Stay | 2 | 2010 | 6479 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2009 | 961 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 1999 | 11071 | 0.020 |
Why?
|
Chymotrypsin | 1 | 2005 | 138 | 0.020 |
Why?
|
Health Care Costs | 1 | 1999 | 3258 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2013 | 936 | 0.020 |
Why?
|
Physical Therapy Modalities | 1 | 2009 | 536 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2013 | 1428 | 0.020 |
Why?
|
American Heart Association | 1 | 2010 | 1081 | 0.020 |
Why?
|
Movement | 1 | 2012 | 1474 | 0.020 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2005 | 119 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2010 | 1180 | 0.020 |
Why?
|
Rhabdomyosarcoma | 1 | 1988 | 359 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2010 | 1110 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2011 | 2362 | 0.020 |
Why?
|
Age Distribution | 1 | 2010 | 2893 | 0.010 |
Why?
|
DNA Damage | 1 | 1994 | 2442 | 0.010 |
Why?
|
Body Burden | 1 | 2005 | 158 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2008 | 10827 | 0.010 |
Why?
|
Rats, Wistar | 1 | 2008 | 1850 | 0.010 |
Why?
|
Cysts | 1 | 1990 | 683 | 0.010 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 267 | 0.010 |
Why?
|
Palliative Care | 1 | 1999 | 3607 | 0.010 |
Why?
|
Leg | 1 | 2009 | 1090 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2016 | 26181 | 0.010 |
Why?
|
Video Recording | 1 | 2009 | 955 | 0.010 |
Why?
|
Exercise Tolerance | 1 | 2009 | 830 | 0.010 |
Why?
|
Smoking | 1 | 2001 | 9073 | 0.010 |
Why?
|
Physical Examination | 1 | 2010 | 1244 | 0.010 |
Why?
|
Warfarin | 1 | 2012 | 1518 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10446 | 0.010 |
Why?
|
Autoantibodies | 1 | 1992 | 2118 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2010 | 1328 | 0.010 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2008 | 1173 | 0.010 |
Why?
|
Ethanol | 1 | 1990 | 1323 | 0.010 |
Why?
|
Relative Biological Effectiveness | 1 | 2005 | 312 | 0.010 |
Why?
|
Health Planning Guidelines | 1 | 2004 | 151 | 0.010 |
Why?
|
Motion | 1 | 2006 | 779 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 16939 | 0.010 |
Why?
|
Diet | 1 | 2001 | 8010 | 0.010 |
Why?
|
Continuity of Patient Care | 1 | 2010 | 1066 | 0.010 |
Why?
|
Choice Behavior | 1 | 2008 | 821 | 0.010 |
Why?
|
Mitral Valve Insufficiency | 1 | 2012 | 1419 | 0.010 |
Why?
|
Cryosurgery | 1 | 2007 | 475 | 0.010 |
Why?
|
Ureteral Obstruction | 1 | 2004 | 292 | 0.010 |
Why?
|
Rats | 2 | 2008 | 23711 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 2011 | 1796 | 0.010 |
Why?
|
Arthritis, Rheumatoid | 1 | 1997 | 3763 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 2013 | 2532 | 0.010 |
Why?
|
Health Policy | 1 | 2013 | 2677 | 0.010 |
Why?
|
Mast Cells | 1 | 2008 | 1390 | 0.010 |
Why?
|
Biophysical Phenomena | 1 | 2001 | 320 | 0.010 |
Why?
|
Anxiety | 2 | 2010 | 4538 | 0.010 |
Why?
|
Biophysics | 1 | 2001 | 380 | 0.010 |
Why?
|
Equipment Safety | 1 | 2001 | 253 | 0.010 |
Why?
|
Eligibility Determination | 1 | 2004 | 421 | 0.010 |
Why?
|
Organ Specificity | 1 | 2005 | 1955 | 0.010 |
Why?
|
Heart Transplantation | 1 | 2013 | 3224 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 1997 | 9185 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2005 | 3602 | 0.010 |
Why?
|
Libido | 1 | 1999 | 119 | 0.010 |
Why?
|
Animals | 4 | 2019 | 167963 | 0.010 |
Why?
|
Coitus | 1 | 1999 | 131 | 0.010 |
Why?
|
Kidney Diseases | 1 | 1990 | 2093 | 0.010 |
Why?
|
Obesity | 1 | 2001 | 12922 | 0.010 |
Why?
|
Pressure | 1 | 2001 | 1156 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16546 | 0.010 |
Why?
|
Leukemia | 1 | 2006 | 1520 | 0.010 |
Why?
|
Genes, Retinoblastoma | 1 | 1997 | 125 | 0.010 |
Why?
|
Drug Industry | 1 | 2004 | 789 | 0.010 |
Why?
|
Proteins | 1 | 2012 | 6029 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 1994 | 10181 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2016 | 12626 | 0.010 |
Why?
|
G1 Phase | 1 | 1997 | 403 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 15789 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 1997 | 717 | 0.010 |
Why?
|
Monitoring, Intraoperative | 1 | 2001 | 942 | 0.010 |
Why?
|
Fatal Outcome | 1 | 1999 | 1832 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2008 | 7593 | 0.010 |
Why?
|
Retinoblastoma Protein | 1 | 1997 | 670 | 0.010 |
Why?
|
Chronic Disease | 1 | 1989 | 9287 | 0.010 |
Why?
|
Adenoviridae | 1 | 1997 | 1084 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2011 | 15840 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2002 | 2418 | 0.010 |
Why?
|
Clinical Competence | 1 | 2008 | 4783 | 0.010 |
Why?
|
Least-Squares Analysis | 1 | 1993 | 369 | 0.010 |
Why?
|
Artifacts | 1 | 2000 | 1898 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2001 | 2907 | 0.010 |
Why?
|
Mesothelioma | 1 | 1997 | 807 | 0.010 |
Why?
|
Cell Separation | 1 | 1997 | 1720 | 0.010 |
Why?
|
Signal Transduction | 1 | 2013 | 23376 | 0.010 |
Why?
|
Physicians | 1 | 2008 | 4591 | 0.010 |
Why?
|
Pain | 1 | 2005 | 5066 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1997 | 6131 | 0.010 |
Why?
|
Sexual Behavior | 1 | 1999 | 2086 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2004 | 4446 | 0.000 |
Why?
|
Genetic Vectors | 1 | 1997 | 3380 | 0.000 |
Why?
|
Recombinant Proteins | 1 | 1997 | 6538 | 0.000 |
Why?
|
Cell Survival | 1 | 1997 | 5797 | 0.000 |
Why?
|
Administration, Cutaneous | 1 | 1990 | 713 | 0.000 |
Why?
|
Flow Cytometry | 1 | 1997 | 5870 | 0.000 |
Why?
|
Alleles | 1 | 1997 | 6898 | 0.000 |
Why?
|
Ultrasonography | 1 | 1997 | 5961 | 0.000 |
Why?
|
Drainage | 1 | 1990 | 1161 | 0.000 |
Why?
|
Liver Neoplasms | 1 | 1999 | 4319 | 0.000 |
Why?
|
Pancreatic Neoplasms | 1 | 1999 | 5351 | 0.000 |
Why?
|